Home › Companies › ALT

Altimmune, Inc.

ALT Lead: Phase 2 8 Biotech Distilled articles ↓

GI/Hepatology Metabolic Neurology Peptide

Most recent annual filing: 2026-03-15

Pipeline (3 active programs)

pemvidutide

ALT-801

Peptide Target: GLP-1 receptor, glucagon receptor

Metabolic Dysfunction-Associated Steatohepatitis Phase 2 subcutaneous
Alcohol Use Disorder Phase 2 subcutaneous
Alcohol-Associated Liver Disease Phase 2 subcutaneous

Biotech Distilled coverage (8)

2026-05-02 UPDATE: Altimmune (ALT) - The Second Whale Surfaces 🔒 Paid
2026-05-01 UPDATE: Altimmune (ALT) - Deep Track Just Showed Its Cards 🔒 Paid
2026-04-27 UPDATE: Altimmune (ALT) - The $4.40 Floor Just Became a $3.00 Ceiling 🔒 Paid
2026-03-21 UPDATE: Altimmune (ALT) - 400 Million Shares?
2026-03-07 UPDATE: Altimmune (ALT) - The $340M War Chest and the Phase 3 Blueprint
2026-01-30 UPDATE: Altimmune (ALT) – The Smart Money Bailout
2026-01-05 UPDATE: The FDA Just Blinked (In a Good Way) – Altimmune Derisked?
2025-12-19 Altimmune, Inc. (ALT): Scientific Due Diligence for Lead and Pipeline Indications

Articles open on Substack. Some deep dives are subscriber-only.